Milestone Pharmaceuticals Inc. Accrued Liabilities, Current
Milestone Pharmaceuticals Inc. (MIST) had Accrued Liabilities, Current of $11.98 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $11.98M.
- 2026-03-31: Accrued Liabilities, Current $9.80M.
- 2025-12-31: Accrued Liabilities, Current $7.64M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $11.98M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $9.80M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $7.64M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |